Direct-acting Antivirals, Used For Hepatitis C, May Reactivate Hepatitis B

Hepatitis C Recall Summary Direct-acting antiviral medications used to treat hepatitis C can reactivate hepatitis B virus in patients who carry it, potentially causing serious liver disease. This affects people across Canada who are taking these medications and have hepatitis B infection. Healthcare providers and patients should be aware of this risk when using these drugs.

Reason

Product safety

Category

consumer product recall

Country

Canada

Agency

HC-PRODUCTS

Recall date

2016-12-01

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-PRODUCTS

Recall details on Nibble Recalls: https://trynibble.app/recalls/210403f8-675f-47d9-be95-27d977204a90